{"id":56524,"date":"2026-02-06T21:36:05","date_gmt":"2026-02-06T13:36:05","guid":{"rendered":"https:\/\/flcube.com\/?p=56524"},"modified":"2026-02-06T21:36:06","modified_gmt":"2026-02-06T13:36:06","slug":"xtalpi-partners-with-visen-pharma-to-accelerate-ai-driven-endocrine-drug-discovery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56524","title":{"rendered":"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery"},"content":{"rendered":"\n<p><strong>XtalPi Inc.<\/strong> (QuantumPharm, <strong><a href=\"https:\/\/www.google.com\/finance\/quote\/2228:HKG\">HKG: 2228<\/a><\/strong>), the Sino\u2011US AI\u2011powered drug discovery platform, has entered a <strong>strategic partnership<\/strong> with <strong>Visen Pharmaceuticals<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/2561:HKG\">HKG: 2561<\/a><\/strong>), the China\u2011based joint venture between Denmark\u2019s <strong>Ascendis Pharma<\/strong> and <strong>Vivo Capital<\/strong>, to co\u2011develop innovative therapies for <strong>endocrine and metabolic disorders<\/strong> using artificial intelligence and robotics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-rationale\">Deal Structure &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>XtalPi Inc. (AI + robotics R&amp;D platform) \u00d7 Visen Pharmaceuticals (endocrine expertise)<\/td><\/tr><tr><td><strong>Visen Ownership<\/strong><\/td><td>JV between Ascendis Pharma (Denmark) and Vivo Capital (China healthcare\u2011focused PE)<\/td><\/tr><tr><td><strong>Focus Area<\/strong><\/td><td>Early\u2011stage discovery and clinical translation in endocrine\/metabolic diseases<\/td><\/tr><tr><td><strong>Target Profile<\/strong><\/td><td>High clinical\u2011value indications and novel targets selected by Visen<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Develop globally competitive &#8220;Made\u2011in\u2011China&#8221; endocrine therapeutics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-integration\">Technology Integration<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>XtalPi Platform:<\/strong> Proprietary <strong>AI + robotics drug R&amp;D infrastructure<\/strong> spanning target identification, molecular generation, and synthesis automation<\/li>\n\n\n\n<li><strong>Visen Expertise:<\/strong> Deep domain knowledge in <strong>endocrine field biology<\/strong>, clinical translation pathways, and unmet need mapping in metabolic disorders<\/li>\n\n\n\n<li><strong>Synergy Model:<\/strong> AI\u2011accelerated hit\u2011to\u2011lead optimization combined with Visen\u2019s target validation and clinical strategy to compress traditional discovery timelines<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-commercial-implications\">Pipeline &amp; Commercial Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Priority<\/th><th>Execution Plan<\/th><\/tr><\/thead><tbody><tr><td><strong>Unmet Clinical Needs<\/strong><\/td><td>Joint early\u2011stage discovery targeting high\u2011value endocrine indications with limited existing therapies<\/td><\/tr><tr><td><strong>Core Pipeline Synergy<\/strong><\/td><td>New programs strategically aligned with Visen\u2019s existing endocrine assets for portfolio acceleration<\/td><\/tr><tr><td><strong>Global Competitiveness<\/strong><\/td><td>Development of innovative &#8220;Made\u2011in\u2011China&#8221; candidates with international regulatory and commercial potential<\/td><\/tr><tr><td><strong>Market Positioning<\/strong><\/td><td>Leverage XtalPi\u2019s AI credibility and Visen\u2019s JV structure to attract follow\u2011on partnerships and licensing interest<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-investor-takeaways\">Market Context &amp; Investor Takeaways<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI\u2011Pharma Convergence:<\/strong> The deal exemplifies the <strong>platform\u2011to\u2011biotech partnership model<\/strong> increasingly favored by investors seeking de\u2011risked discovery engines without full vertical integration costs.<\/li>\n\n\n\n<li><strong>China Biotech Globalization:<\/strong> &#8220;Made\u2011in\u2011China, Global\u2011Standard&#8221; positioning addresses prior concerns about domestic\u2011only development strategies, enhancing Visen\u2019s appeal to international licensors.<\/li>\n\n\n\n<li><strong>Ascendis\/Vivo Validation:<\/strong> Visen\u2019s ability to attract tier\u2011one AI partners reinforces the JV\u2019s strategic value and may accelerate Ascendis Pharma\u2019s China market penetration through local innovation.<\/li>\n\n\n\n<li><strong>XtalPi Ecosystem Expansion:<\/strong> Partnership adds specialized therapeutic area depth to XtalPi\u2019s platform, supporting recurring revenue diversification beyond standalone software licensing.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the XtalPi\u2011Visen partnership timeline, discovery program progression, and commercial potential of jointly developed endocrine therapies. Actual results may differ due to scientific risks, regulatory requirements, and competitive dynamics in the metabolic disease space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino\u2011US AI\u2011powered drug discovery platform, has entered a strategic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56528,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,93],"tags":[392,1112,4363,695,393,696],"class_list":["post-56524","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-digital","tag-ascendis-pharma","tag-hkg-2228","tag-hkg-2561","tag-quantumpharm","tag-visen-pharmaceuticals","tag-xtalpi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino\u2011US AI\u2011powered drug discovery platform, has entered a strategic partnership with Visen Pharmaceuticals (HKG: 2561), the China\u2011based joint venture between Denmark\u2019s Ascendis Pharma and Vivo Capital, to co\u2011develop innovative therapies for endocrine and metabolic disorders using artificial intelligence and robotics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56524\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery\" \/>\n<meta property=\"og:description\" content=\"XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino\u2011US AI\u2011powered drug discovery platform, has entered a strategic partnership with Visen Pharmaceuticals (HKG: 2561), the China\u2011based joint venture between Denmark\u2019s Ascendis Pharma and Vivo Capital, to co\u2011develop innovative therapies for endocrine and metabolic disorders using artificial intelligence and robotics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56524\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T13:36:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T13:36:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery\",\"datePublished\":\"2026-02-06T13:36:05+00:00\",\"dateModified\":\"2026-02-06T13:36:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0606.webp\",\"keywords\":[\"Ascendis Pharma\",\"HKG: 2228\",\"HKG: 2561\",\"QuantumPharm\",\"Visen Pharmaceuticals\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Deals\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56524#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56524\",\"name\":\"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0606.webp\",\"datePublished\":\"2026-02-06T13:36:05+00:00\",\"dateModified\":\"2026-02-06T13:36:06+00:00\",\"description\":\"XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino\u2011US AI\u2011powered drug discovery platform, has entered a strategic partnership with Visen Pharmaceuticals (HKG: 2561), the China\u2011based joint venture between Denmark\u2019s Ascendis Pharma and Vivo Capital, to co\u2011develop innovative therapies for endocrine and metabolic disorders using artificial intelligence and robotics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56524\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0606.webp\",\"width\":1080,\"height\":608,\"caption\":\"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56524#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery - Insight, China&#039;s Pharmaceutical Industry","description":"XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino\u2011US AI\u2011powered drug discovery platform, has entered a strategic partnership with Visen Pharmaceuticals (HKG: 2561), the China\u2011based joint venture between Denmark\u2019s Ascendis Pharma and Vivo Capital, to co\u2011develop innovative therapies for endocrine and metabolic disorders using artificial intelligence and robotics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56524","og_locale":"en_US","og_type":"article","og_title":"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery","og_description":"XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino\u2011US AI\u2011powered drug discovery platform, has entered a strategic partnership with Visen Pharmaceuticals (HKG: 2561), the China\u2011based joint venture between Denmark\u2019s Ascendis Pharma and Vivo Capital, to co\u2011develop innovative therapies for endocrine and metabolic disorders using artificial intelligence and robotics.","og_url":"https:\/\/flcube.com\/?p=56524","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T13:36:05+00:00","article_modified_time":"2026-02-06T13:36:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56524#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56524"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery","datePublished":"2026-02-06T13:36:05+00:00","dateModified":"2026-02-06T13:36:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56524"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56524#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0606.webp","keywords":["Ascendis Pharma","HKG: 2228","HKG: 2561","QuantumPharm","Visen Pharmaceuticals","Xtalpi"],"articleSection":["Company","Deals","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56524#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56524","url":"https:\/\/flcube.com\/?p=56524","name":"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56524#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56524#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0606.webp","datePublished":"2026-02-06T13:36:05+00:00","dateModified":"2026-02-06T13:36:06+00:00","description":"XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino\u2011US AI\u2011powered drug discovery platform, has entered a strategic partnership with Visen Pharmaceuticals (HKG: 2561), the China\u2011based joint venture between Denmark\u2019s Ascendis Pharma and Vivo Capital, to co\u2011develop innovative therapies for endocrine and metabolic disorders using artificial intelligence and robotics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56524#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56524"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56524#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0606.webp","width":1080,"height":608,"caption":"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56524#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"XtalPi Partners with Visen Pharma to Accelerate AI\u2011Driven Endocrine Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56524"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56524\/revisions"}],"predecessor-version":[{"id":56529,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56524\/revisions\/56529"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56528"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}